Please login to the form below

Not currently logged in
Email:
Password:

Lexicon

This page shows the latest Lexicon news and features for those working in and with pharma, biotech and healthcare.

Ipsen searches for new CEO after splitting top roles

Ipsen searches for new CEO after splitting top roles

Ipsen licenses the drug from Lexicon Pharmaceuticals and has rights outside the US and Japan.

Latest news

  • Sanofi and Lexicon collaborate on new medication for diabetes Sanofi and Lexicon collaborate on new medication for diabetes

    Sanofi and Lexicon collaborate on new medication for diabetes. Plan to develop new investigational drugsotagliflozin. ... Pascale Witz, executive VP at Sanofi, said: “ This agreement with Lexicon reinforces our commitment to helping people living with

  • Jon Linscott: If I could change one thing... Jon Linscott: If I could change one thing...

    While integration, engagement and digital have been exciting additions to the marketer's lexicon we must not forget the language of our customers - which is value, choice and patient-centred.

  • Lexicon announces IBS trial results

    Lexicon announces IBS trial results. Lexicon Pharmaceuticals’ TPH inhibitor LX1031 has been shown in a phase II trial to be well tolerated and provide clinical benefit to patients with irritable bowel ... doses. Lexicon now intends to advance LX1033

  • Speaking of value

    Value demonstration should be based on a consistent lexicon for communicating the performance of medicines.

  • Before his Pharmacopeia appointment, Kimball was vice-president of medicinal chemistry at Lexicon.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Six degrees of participation Six degrees of participation

    Similarly, social listening is a great way of understanding the patient lexicon.

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Indeed, it challenges the validity of the term ‘asthma’in the modern day medical lexicon at all.

  • Deal Watch November 2016 Deal Watch November 2016

    Strategic alliance, options. 122.7 per. BMS/ Lexicon Pharmaceuticals. BMS-986176 for neutopathic pain (pc) plus other small molecules that act on same target.

  • Deal Watch November 2015 Deal Watch November 2015

    Under the agreement Lexicon receives an upfront payment of $300m with a further $1.4bn in development, regulatory and sales milestones. ... Lexicon will continue to lead the development programme and has retained commercial rights to type 1 diabetes in

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    For multivalent MVA-BN Filovirus vaccine. 187. Lexicon Pharmaceuticals/Ipsen. Licence [B]. Telotristat etiprate in P3 for carcinoid syndrome.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics